HRP20211850T1 - Farmakološki aktivni aliciklički supstituirani pirazolo[1,5-a]pirimidin derivati - Google Patents
Farmakološki aktivni aliciklički supstituirani pirazolo[1,5-a]pirimidin derivati Download PDFInfo
- Publication number
- HRP20211850T1 HRP20211850T1 HRP20211850TT HRP20211850T HRP20211850T1 HR P20211850 T1 HRP20211850 T1 HR P20211850T1 HR P20211850T T HRP20211850T T HR P20211850TT HR P20211850 T HRP20211850 T HR P20211850T HR P20211850 T1 HRP20211850 T1 HR P20211850T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- carboxylic acid
- pyrazolo
- trifluoromethyl
- cyclohexyl
- Prior art date
Links
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- -1 racemates Chemical class 0.000 claims 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 6
- 230000003287 optical effect Effects 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- WHSWIVIVQJQEEG-RXSFTSLZSA-N FC=1C(=NN2C=1N=C(C(=C2N1C[C@](CCC1)(C(=O)O)C)OC)C)[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound FC=1C(=NN2C=1N=C(C(=C2N1C[C@](CCC1)(C(=O)O)C)OC)C)[C@@H]1CC[C@H](CC1)C(F)(F)F WHSWIVIVQJQEEG-RXSFTSLZSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- XGUVQTSNLOXPQT-JOCHJYFZSA-N (3R)-1-[2-(4,4-difluorocyclohexyl)-3-fluoro-5-methyl-6-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl]-3-methylpiperidine-3-carboxylic acid Chemical compound FC1(CCC(CC1)C1=NN2C(N=C(C(=C2N2C[C@@](CCC2)(C(=O)O)C)C(C)C)C)=C1F)F XGUVQTSNLOXPQT-JOCHJYFZSA-N 0.000 claims 1
- RUGCBFURIOPNHR-JOCHJYFZSA-N (3R)-1-[2-(4,4-difluorocyclohexyl)-5,6-diethylpyrazolo[1,5-a]pyrimidin-7-yl]-3-methylpiperidine-3-carboxylic acid Chemical compound FC1(CCC(CC1)C1=NN2C(N=C(C(=C2N2C[C@@](CCC2)(C(=O)O)C)CC)CC)=C1)F RUGCBFURIOPNHR-JOCHJYFZSA-N 0.000 claims 1
- UTYQOINWQJGILD-HSZRJFAPSA-N (3R)-1-[2-(4,4-difluorocyclohexyl)-5-methyl-6-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylpiperidine-3-carboxylic acid Chemical compound FC1(CCC(CC1)C1=NN2C(N=C(C(=C2N2C[C@@](CCC2)(C(=O)O)CC)C(C)C)C)=C1)F UTYQOINWQJGILD-HSZRJFAPSA-N 0.000 claims 1
- NPSUCBFOGBVWFQ-JOCHJYFZSA-N (3R)-1-[2-(4,4-difluorocyclohexyl)-5-methyl-6-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl]-3-methylpiperidine-3-carboxylic acid Chemical compound FC1(CCC(CC1)C1=NN2C(N=C(C(=C2N2C[C@@](CCC2)(C(=O)O)C)C(C)C)C)=C1)F NPSUCBFOGBVWFQ-JOCHJYFZSA-N 0.000 claims 1
- UTYQOINWQJGILD-QHCPKHFHSA-N (3S)-1-[2-(4,4-difluorocyclohexyl)-5-methyl-6-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylpiperidine-3-carboxylic acid Chemical compound FC1(CCC(CC1)C1=NN2C(N=C(C(=C2N2C[C@](CCC2)(C(=O)O)CC)C(C)C)C)=C1)F UTYQOINWQJGILD-QHCPKHFHSA-N 0.000 claims 1
- NPSUCBFOGBVWFQ-QFIPXVFZSA-N (3S)-1-[2-(4,4-difluorocyclohexyl)-5-methyl-6-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl]-3-methylpiperidine-3-carboxylic acid Chemical compound FC1(CCC(CC1)C1=NN2C(N=C(C(=C2N2C[C@](CCC2)(C(=O)O)C)C(C)C)C)=C1)F NPSUCBFOGBVWFQ-QFIPXVFZSA-N 0.000 claims 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical class OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims 1
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- LYVXPYOVFRWPFH-HOZJOUCCSA-N C(#N)C=1C(=NN2C=1N=C(C(=C2N1C[C@@](CCC1)(C(=O)O)C)C(C)C)C)[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound C(#N)C=1C(=NN2C=1N=C(C(=C2N1C[C@@](CCC1)(C(=O)O)C)C(C)C)C)[C@@H]1CC[C@H](CC1)C(F)(F)F LYVXPYOVFRWPFH-HOZJOUCCSA-N 0.000 claims 1
- LYVXPYOVFRWPFH-UAVUOLJFSA-N C(#N)C=1C(=NN2C=1N=C(C(=C2N1C[C@](CCC1)(C(=O)O)C)C(C)C)C)[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound C(#N)C=1C(=NN2C=1N=C(C(=C2N1C[C@](CCC1)(C(=O)O)C)C(C)C)C)[C@@H]1CC[C@H](CC1)C(F)(F)F LYVXPYOVFRWPFH-UAVUOLJFSA-N 0.000 claims 1
- SZJRXJJYMMCDEM-XCGNWRKASA-N C(C)C=1C(=NC=2N(C=1N1C[C@@](CCC1)(C(=O)O)C)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C Chemical compound C(C)C=1C(=NC=2N(C=1N1C[C@@](CCC1)(C(=O)O)C)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C SZJRXJJYMMCDEM-XCGNWRKASA-N 0.000 claims 1
- SADJPECUPDDDQB-XCGNWRKASA-N C(C)[C@@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)OC)C(=O)O Chemical compound C(C)[C@@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)OC)C(=O)O SADJPECUPDDDQB-XCGNWRKASA-N 0.000 claims 1
- LVBMNSAYEQVFQA-DOQJBMMISA-N C(C)[C@@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2F)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)OC)C(=O)O Chemical compound C(C)[C@@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2F)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)OC)C(=O)O LVBMNSAYEQVFQA-DOQJBMMISA-N 0.000 claims 1
- LVBMNSAYEQVFQA-DFFLPILJSA-N C(C)[C@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2F)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)OC)C(=O)O Chemical compound C(C)[C@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2F)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)OC)C(=O)O LVBMNSAYEQVFQA-DFFLPILJSA-N 0.000 claims 1
- ZGAWLQDDQDAAFE-QQMNAOGKSA-N CC(C)C1=C(N2N=C(C=C2N=C1C)[C@H]1CC[C@@H](CC1)C(F)(F)F)N1CCC[C@@](C)(C1)C(O)=O Chemical compound CC(C)C1=C(N2N=C(C=C2N=C1C)[C@H]1CC[C@@H](CC1)C(F)(F)F)N1CCC[C@@](C)(C1)C(O)=O ZGAWLQDDQDAAFE-QQMNAOGKSA-N 0.000 claims 1
- DMFLJSHKIOZINU-BRWVUGGUSA-N CC(C)C1=C(N2N=C(C=C2N=C1C)[C@H]1CC[C@@H](CC1)C(F)(F)F)N1CCC[C@H](C1)C(O)=O Chemical compound CC(C)C1=C(N2N=C(C=C2N=C1C)[C@H]1CC[C@@H](CC1)C(F)(F)F)N1CCC[C@H](C1)C(O)=O DMFLJSHKIOZINU-BRWVUGGUSA-N 0.000 claims 1
- NAZGPTRCCWEEBK-MHPIHPPYSA-N CC(C)C1=C(N2N=C(C=C2N=C1C)[C@H]1CC[C@@H](CC1)C(F)(F)F)N1CCC[C@](C1)(C(C)C)C(O)=O Chemical compound CC(C)C1=C(N2N=C(C=C2N=C1C)[C@H]1CC[C@@H](CC1)C(F)(F)F)N1CCC[C@](C1)(C(C)C)C(O)=O NAZGPTRCCWEEBK-MHPIHPPYSA-N 0.000 claims 1
- VIKYRFJZDYMDMY-KXNSMUHISA-N CC(C)C1=C(N2N=C([C@H]3CC[C@@H](CC3)C(F)(F)F)C(F)=C2N=C1C)N1CCC[C@@](C)(C1)C(O)=O Chemical compound CC(C)C1=C(N2N=C([C@H]3CC[C@@H](CC3)C(F)(F)F)C(F)=C2N=C1C)N1CCC[C@@](C)(C1)C(O)=O VIKYRFJZDYMDMY-KXNSMUHISA-N 0.000 claims 1
- VIKYRFJZDYMDMY-CKNGIIGNSA-N CC(C)C1=C(N2N=C([C@H]3CC[C@@H](CC3)C(F)(F)F)C(F)=C2N=C1C)N1CCC[C@](C)(C1)C(O)=O Chemical compound CC(C)C1=C(N2N=C([C@H]3CC[C@@H](CC3)C(F)(F)F)C(F)=C2N=C1C)N1CCC[C@](C)(C1)C(O)=O VIKYRFJZDYMDMY-CKNGIIGNSA-N 0.000 claims 1
- NAZGPTRCCWEEBK-MPCDZSKCSA-N CC1=NC=2N(C(=C1C(C)C)N1C[C@@](CCC1)(C(=O)O)C(C)C)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound CC1=NC=2N(C(=C1C(C)C)N1C[C@@](CCC1)(C(=O)O)C(C)C)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F NAZGPTRCCWEEBK-MPCDZSKCSA-N 0.000 claims 1
- AVJDMXZYANABIA-MPCDZSKCSA-N CC1=NC=2N(C(=C1C(C)C)N1C[C@@](CCC1)(C(=O)O)CCC)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound CC1=NC=2N(C(=C1C(C)C)N1C[C@@](CCC1)(C(=O)O)CCC)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F AVJDMXZYANABIA-MPCDZSKCSA-N 0.000 claims 1
- DMFLJSHKIOZINU-ULQDDVLXSA-N CC1=NC=2N(C(=C1C(C)C)N1C[C@H](CCC1)C(=O)O)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound CC1=NC=2N(C(=C1C(C)C)N1C[C@H](CCC1)C(=O)O)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F DMFLJSHKIOZINU-ULQDDVLXSA-N 0.000 claims 1
- AVJDMXZYANABIA-MHPIHPPYSA-N CC1=NC=2N(C(=C1C(C)C)N1C[C@](CCC1)(C(=O)O)CCC)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound CC1=NC=2N(C(=C1C(C)C)N1C[C@](CCC1)(C(=O)O)CCC)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F AVJDMXZYANABIA-MHPIHPPYSA-N 0.000 claims 1
- SHIQMGZZVCRUAO-UAVUOLJFSA-N CC[C@@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=C(F)C(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O Chemical compound CC[C@@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=C(F)C(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O SHIQMGZZVCRUAO-UAVUOLJFSA-N 0.000 claims 1
- SXKMLBUUIVALCM-XFAGBWLFSA-N CC[C@@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=CC(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O Chemical compound CC[C@@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=CC(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O SXKMLBUUIVALCM-XFAGBWLFSA-N 0.000 claims 1
- SADJPECUPDDDQB-WCJKSRRJSA-N CC[C@@]1(CCCN(C1)C1=C(OC)C(C)=NC2=CC(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O Chemical compound CC[C@@]1(CCCN(C1)C1=C(OC)C(C)=NC2=CC(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O SADJPECUPDDDQB-WCJKSRRJSA-N 0.000 claims 1
- SHIQMGZZVCRUAO-HOZJOUCCSA-N CC[C@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=C(F)C(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O Chemical compound CC[C@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=C(F)C(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O SHIQMGZZVCRUAO-HOZJOUCCSA-N 0.000 claims 1
- SXKMLBUUIVALCM-QZTZHPFYSA-N CC[C@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=CC(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O Chemical compound CC[C@]1(CCCN(C1)C1=C(C(C)C)C(C)=NC2=CC(=NN12)[C@H]1CC[C@@H](CC1)C(F)(F)F)C(O)=O SXKMLBUUIVALCM-QZTZHPFYSA-N 0.000 claims 1
- CHXRKXFQNDOVPF-SEPYTNNBSA-N COCCC=1C(=NC=2N(C=1N1C[C@@](CCC1)(C(=O)O)C)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C Chemical compound COCCC=1C(=NC=2N(C=1N1C[C@@](CCC1)(C(=O)O)C)N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C CHXRKXFQNDOVPF-SEPYTNNBSA-N 0.000 claims 1
- AGPHNAQRSJNYHH-CKNGIIGNSA-N C[C@@]1(CN(CCC1)C=1N2C(N=C3CCCCC=13)=CC(=N2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O Chemical compound C[C@@]1(CN(CCC1)C=1N2C(N=C3CCCCC=13)=CC(=N2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O AGPHNAQRSJNYHH-CKNGIIGNSA-N 0.000 claims 1
- CIDLXSIIKQLZLL-WWMOSFEBSA-N C[C@@]1(CN(CCC1)C=1N2C(N=C3CCC[C@@H](C=13)C)=CC(=N2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O Chemical compound C[C@@]1(CN(CCC1)C=1N2C(N=C3CCC[C@@H](C=13)C)=CC(=N2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O CIDLXSIIKQLZLL-WWMOSFEBSA-N 0.000 claims 1
- CIDLXSIIKQLZLL-FBPDVEOQSA-N C[C@@]1(CN(CCC1)C=1N2C(N=C3CCC[C@H](C=13)C)=CC(=N2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O Chemical compound C[C@@]1(CN(CCC1)C=1N2C(N=C3CCC[C@H](C=13)C)=CC(=N2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O CIDLXSIIKQLZLL-FBPDVEOQSA-N 0.000 claims 1
- DRENYLRLZYSFGR-HOZJOUCCSA-N C[C@@]1(CN(CCC1)C=1N2N=C(C=C2N=C2CCCCCC=12)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O Chemical compound C[C@@]1(CN(CCC1)C=1N2N=C(C=C2N=C2CCCCCC=12)[C@@H]1CC[C@H](CC1)C(F)(F)F)C(=O)O DRENYLRLZYSFGR-HOZJOUCCSA-N 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- RZWACFXRVLCYDS-QQMNAOGKSA-N FC[C@@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)C(C)C)C(=O)O Chemical compound FC[C@@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)C(C)C)C(=O)O RZWACFXRVLCYDS-QQMNAOGKSA-N 0.000 claims 1
- RZWACFXRVLCYDS-SEPYTNNBSA-N FC[C@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)C(C)C)C(=O)O Chemical compound FC[C@]1(CN(CCC1)C1=C(C(=NC=2N1N=C(C=2)[C@@H]1CC[C@H](CC1)C(F)(F)F)C)C(C)C)C(=O)O RZWACFXRVLCYDS-SEPYTNNBSA-N 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 150000007960 acetonitrile Chemical class 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1700108A HU231058B1 (hu) | 2017-03-13 | 2017-03-13 | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| PCT/IB2018/051599 WO2018167630A1 (en) | 2017-03-13 | 2018-03-12 | PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES |
| EP18713016.6A EP3596080B1 (en) | 2017-03-13 | 2018-03-12 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211850T1 true HRP20211850T1 (hr) | 2022-03-04 |
Family
ID=89992389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211850TT HRP20211850T1 (hr) | 2017-03-13 | 2018-03-12 | Farmakološki aktivni aliciklički supstituirani pirazolo[1,5-a]pirimidin derivati |
Country Status (32)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| EP4424683A3 (en) | 2017-03-13 | 2024-11-06 | Lundbeck La Jolla Research Center, Inc. | Dual magl and faah inhibitors |
| PE20221836A1 (es) | 2020-03-26 | 2022-11-29 | Richter Gedeon Nyrt | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5 |
| WO2022029666A1 (en) | 2020-08-05 | 2022-02-10 | Richter Gedeon Nyrt. | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN115872095A (zh) * | 2022-11-28 | 2023-03-31 | 南通三鑫车灯配件有限公司 | 一种汽车车灯反光罩的生产线流转装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2290885T3 (es) | 2004-03-02 | 2008-02-16 | F. Hoffmann-La Roche Ag | Derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina y compuestos afines como ligandos para el receptor gaba para el tratamiento de la ansiedad, depresion y epilepsia. |
| GB0512844D0 (en) | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
| KR100753017B1 (ko) * | 2006-05-25 | 2007-08-30 | 한국화학연구원 | 7-(3,4-디알콕시페닐)-피라졸로[1,5-ａ]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물 |
| JP5432982B2 (ja) | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | アポトーシスシグナル調節キナーゼ１阻害剤 |
| TWI648281B (zh) | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | 含硫二環式化合物 |
| US9828381B2 (en) * | 2015-04-20 | 2017-11-28 | AbbVie Deutschland GmbH & Co. KG | Substituted pyrazolopyrimidines and method of use |
| JP2018199623A (ja) | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
-
2017
- 2017-03-13 HU HU1700108A patent/HU231058B1/hu not_active IP Right Cessation
-
2018
- 2018-03-12 EA EA201992127A patent/EA038756B1/ru unknown
- 2018-03-12 AU AU2018235266A patent/AU2018235266B2/en not_active Ceased
- 2018-03-12 JP JP2019549366A patent/JP7153662B2/ja active Active
- 2018-03-12 DK DK18713016.6T patent/DK3596080T3/da active
- 2018-03-12 MY MYPI2019004947A patent/MY195262A/en unknown
- 2018-03-12 ES ES18713016T patent/ES2893824T3/es active Active
- 2018-03-12 HR HRP20211850TT patent/HRP20211850T1/hr unknown
- 2018-03-12 HU HUE18713016A patent/HUE056562T2/hu unknown
- 2018-03-12 PE PE2019001773A patent/PE20191646A1/es unknown
- 2018-03-12 CA CA3056185A patent/CA3056185A1/en active Pending
- 2018-03-12 GE GEAP201815192A patent/GEP20217256B/en unknown
- 2018-03-12 UA UAA201910328A patent/UA124783C2/uk unknown
- 2018-03-12 MX MX2019011000A patent/MX2019011000A/es unknown
- 2018-03-12 LT LTEPPCT/IB2018/051599T patent/LT3596080T/lt unknown
- 2018-03-12 PT PT18713016T patent/PT3596080T/pt unknown
- 2018-03-12 KR KR1020197028833A patent/KR20190127779A/ko not_active Ceased
- 2018-03-12 BR BR112019018843A patent/BR112019018843A2/pt not_active Application Discontinuation
- 2018-03-12 CN CN201880017859.XA patent/CN110431142A/zh active Pending
- 2018-03-12 SI SI201830495T patent/SI3596080T1/sl unknown
- 2018-03-12 PL PL18713016T patent/PL3596080T3/pl unknown
- 2018-03-12 US US16/493,453 patent/US11026946B2/en active Active
- 2018-03-12 EP EP18713016.6A patent/EP3596080B1/en active Active
- 2018-03-12 SG SG11201907864YA patent/SG11201907864YA/en unknown
- 2018-03-12 WO PCT/IB2018/051599 patent/WO2018167630A1/en not_active Ceased
- 2018-03-12 RS RS20211334A patent/RS62533B1/sr unknown
- 2018-03-13 AR ARP180100580A patent/AR111176A1/es unknown
-
2019
- 2019-08-26 IL IL26892319A patent/IL268923A/en unknown
- 2019-08-27 PH PH12019501968A patent/PH12019501968A1/en unknown
- 2019-09-12 CL CL2019002601A patent/CL2019002601A1/es unknown
- 2019-09-18 CO CONC2019/0010120A patent/CO2019010120A2/es unknown
- 2019-10-10 EC ECSENADI201972975A patent/ECSP19072975A/es unknown
-
2021
- 2021-11-08 CY CY20211100964T patent/CY1124708T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211850T1 (hr) | Farmakološki aktivni aliciklički supstituirani pirazolo[1,5-a]pirimidin derivati | |
| ES2638850T3 (es) | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos | |
| ES2549087T3 (es) | Derivados de aminodihidrotiazina como inhibidores de BACE para el tratamiento de la enfermedad de Alzheimer | |
| JP2020510041A5 (enExample) | ||
| CN109641898A (zh) | 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 | |
| CA3118908A1 (en) | Pyridazinone compounds and uses thereof | |
| JP2009529047A5 (enExample) | ||
| RU2008101923A (ru) | Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора | |
| KR101965326B1 (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
| RU2350616C2 (ru) | Производные пиразоло- и имидазопиримидина | |
| JP2012527483A (ja) | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 | |
| JP2012501313A5 (enExample) | ||
| RU2015108898A (ru) | 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ | |
| JP2022508657A (ja) | アミノ酸化合物およびその使用方法 | |
| AU2013283239A1 (en) | Thienopyridone derivatives useful as activators of AMPK | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| TW201632523A (zh) | ４，６-經取代之吡唑并［１，５-ａ］吡 | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| JP2020514341A5 (enExample) | ||
| JP2011503199A (ja) | 関節炎の治療方法 | |
| NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| KR20170040299A (ko) | 이미다조피리다진 화합물 | |
| HRP20130918T1 (hr) | Derivati 4-aminopirimidina kao receptori antagonista histamina h4 | |
| WO2009127944A8 (en) | Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors |